Teva Pharmaceutical Industries’ Anti-IL-15 Antibody Shows Promise in Vitiligo Study

Data ReadoutpositiveAnti-IL-15 AntibodyPositive

AI Analysis

Summary

Teva Pharmaceutical's anti-IL-15 antibody demonstrated promise in a vitiligo study. The preliminary positive data suggests potential therapeutic benefit for this autoimmune skin condition.

Clinical Trial Data

Importance:5/10

Sentiment:

0.60

vitiligoimmunologyantibodyclinical trial

Related Companies

$TEVA

Read the original article

Published by yahoo_finance on July 12, 2026 10:02 PM

Read Original